The current findings proposed innovative cancer drug discovery targeting class 1 HDACs, highlighting LIG1 and LIG2 as potential inhibitors for cancer treatment, emphasizing their interaction pattern and stability in bounded complexes. Here, LIG3 is linked to cancer.